Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Apple and Dell Technologies rise sharply after the Trump administration exempts smartphones, computers, memory ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

Eli Lilly (LLY) stock and Johnson & Johnson (JNJ) stock are upgraded and Pfizer (PFE) stock and AbbVie (ABBV) stock downgraded at Goldman Sachs. Read more here.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFECL) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (BIT:1PFE) from Buy to Neutral. As of April 4, 2025, the average one-year price target for Pfizer is €28. ...

Goldman maintains two custom equity baskets, each with 50 stocks from the Russell 1000 Index, to monitor this trend. The firm rebalanced both baskets, including the High Liquidity (GSTHLLIQ) portfolio ...

Goldman Sachs downgraded Pfizer (PFE) to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The ...

Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on ...